Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Employees work at a Fosun Pharmaceuticals facility in Shanghai. Photo: Handout
Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
Alibaba

Alibaba open-sources AI model that can detect cancer and nearly 150 conditions

Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

Biomedicine: Industry Trends

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
AI is increasingly being used in the design of novel drugs. Photo: Shutterstock Images
Biomedicine: Industry Trends

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

Advertisement
Advertisement
Advertisement
IPO

Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO

Regulator cites ‘serious concerns’ about ‘artificial impression of demand’ in US-based company’s US$78 million listing in 2025.

Hong Kong's market regulator considered the suspension “necessary or expedient to maintain an orderly and fair market”. Photo: Handout
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Technology

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

videocam
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

The expansion of China’s biotechnology industry is driving up demand for primates. Photo: Shutterstock
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
The firms join a broader trend of hi-tech firms flocking to the Shanghai Stock Exchange’s Nasdaq-style Star Market. Photo: Xinhua
Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Artificial intelligence

Biomedicine | China thinks big on brain-computer interfaces

Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.

China thinks big on brain-computer interfaces after world-first surgery
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

China’s biopharmaceutical firms are increasingly looking to compete directly on the global market. Photo: Shutterstock
Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Advertisement
Advertisement
Advertisement
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Asset id: 2156561481 Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock Images
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
Researchers have engineered brewer’s yeast to produce catharanthine – the direct precursor to the cancer treatment vinblastine. Photo: Getty Images/iStockphoto
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

Test tubes are arranged in front of an AstraZeneca logo in this illustration picture taken May 21, 2021. Photo: Reuters
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Clara Chan Ka-chai, CEO of Hong Kong Investment Corporation (HKIC) Photo: Enoch Yiu
Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement